Deal is the fifth largest robotics surgery purchase ever, and the second big move from Stryker.
The Danish group tops the list, while Ardelyx could get its first nod for tenapanor, and Xeris gets a second shot with its hypoglycaemia rescue pen.
Spending $95m to speed up the anaemia project’s path to approval could be worth the investment for Astrazeneca.
Nucana’s recent setback with Acelarin adds to the long list of pancreatic cancer failures, and a look at the late-stage pipeline shows little concrete progress.
Astrazeneca gets a win for its SGLT2 in heart failure irrespective of diabetes status, but Lilly and Boehringer’s Jardiance isn’t far behind.
Patent expiries and challenges have done little to halt the sales of some of the industry's biggest products.
Blaming manufacturing delays and competitive pressure, Autolus asks investors to reset expectations.
As J&J tears up a licensing deal with Alligator, CD40 agonism might join the likes of Ox40 and IDO as an immuno-oncology approach that has failed to deliver.